Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Impilo on the establishment of a continuation fund
Mandate

Vinge advises Impilo on the establishment of a continuation fund

November 15, 2024

Vinge has advised Impilo with regulatory advice on the establishment of Impilo Orphan Drugs, a so-called continuation fund. The continuation fund will have EUR 320m in commitments and will invest in Immedica, in which KKR recently became an owner alongside Impilo.

Impilo is a Nordic investment company specializing in investments within the pharmaceutical, medical technology, healthcare services and other health-related industries. Impilo holds a highly diversified portfolio of healthcare investments and manages approximately EUR 1 billion in capital, from leading Nordic and international investors.

Vinges team consisted of Nils Unckel, Anton Sjökvist and Viktoria Wnuk.

Related

Vinge advises in connection with data center provider EcoDataCenter’s issue of SEK 500 million senior unsecured bonds

Vinge has advised ABG Sundal Collier in connection with EcoDC Holding AB (publ)'s issue of SEK 500 million senior unsecured bonds, within a framework of up to SEK 2 billion.
November 28, 2025

Vinge has advised Northmill Group AB in connection with the issuance of tier 2 capital bonds (T2)

 Vinge has advised Northmill Group AB in connection with its successful issuance of SEK 100 million tier 2 capital bonds (T2) with a floating rate interest of 3-month STIBOR + 650 basis points.
November 26, 2025

Vinge has advised Fortinova Fastigheter in connection with its uplisting to Nasdaq Stockholm

 Vinge has advised Fortinova Fastigheter AB (publ) in connection with its list change from Nasdaq First North Premier Growth Market to Nasdaq Stockholm. The prospectus was published on 12 November 2025 and the trading on Nasdaq Stockholm commenced on 19 November 2025, five years to the day since the first listing.
November 19, 2025